Trial reportPloS one2017
The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci.
Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Identifying the genetic associations among the psoriasis patients in eastern India.Journal of human genetics · 2024Article
- Deep learning captures the effect of epistasis in multifactorial diseases.Frontiers in medicine · 2024Article
- Selected miRNA and Psoriasis-Cardiovascular Disease (CVD)-Overweight/Obesity Network-A Pilot Study.International journal of molecular sciences · 2023Article
- Diagnostic Test Accuracy of Genetic Tests in Diagnosing Psoriasis: A Systematic Review.Cureus · 2022Review
- Analysis of selected genetic variants in psoriasis susceptibility and response to treatment.Postepy dermatologii i alergologii · 2022Article
- The Analysis of a Genome-Wide Association Study (GWAS) of Overweight and Obesity in Psoriasis.International journal of molecular sciences · 2022Article
- PSORS1 Locus Genotyping Profile in Psoriasis: A Pilot Case-Control Study.Diagnostics (Basel, Switzerland) · 2022Article
- Olfactomedin-4 improves cutaneous wound healing by promoting skin cell proliferation and migration through POU5F1/OCT4 and ESR1 signalling cascades.Cellular and molecular life sciences : CMLS · 2022Article
- Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?World journal of diabetes · 2021Article
- Emerging Roles of MHC Class I Region-Encoded E3 Ubiquitin Ligases in Innate Immunity.Frontiers in immunology · 2021Review
- Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.Journal of personalized medicine · 2020Article
- Psoriasis and Genetics.Acta dermato-venereologica · 2020Review
- Long Noncoding RNACells · 2019Review
- Value of multilocus genetic risk score for atrial fibrillation in end-stage kidney disease patients in a Polish population.Scientific reports · 2018Article
- Psoriasis: from Pathogenesis to Targeted Therapies.Clinical reviews in allergy & immunology · 2018Review
- Precision Medicine in Lifestyle Medicine: The Way of the Future?American journal of lifestyle medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo confirm the association of previously discovered psoriasis (Ps) risk loci with the disease in a Polish population and to create predictive models based on the combination of these single nucleotide polymorphisms (SNPs). MATERIAL AND
methodsThirty-eight SNPs were genotyped in 480 Ps patients and 490 controls. Alleles distributions were compared between patients and controls, as well as between different Ps sub-phenotypes. The genetic risk score (GRS) was calculated to assess the cumulative risk conferred by multiple loci.
resultsWe confirmed associations of several loci with Ps: HLA-C, REL, IL12B, TRIM39/RPP21, POU5F1, MICA. The analysis of ROC curves showed that GRS combining 16 SNPs at least nominally (uncorrected P<0.05) associated with Ps (GRS-N) had significantly better discriminative power than GRS combining SNPs associated with Ps after the Bonferroni correction (AUC 0.776 vs. 0.750, P = 1 x 10-4) or HLA-C (AUC 0.776 vs. 0.694, P<1 x 10-5). On the other hand, adding additional SNPs to the model did not improve its discriminatory ability (AUC 0.782 for GRS combining all SNPs, P>0.05). In order to assess the total risk conferred by GRS-N, we calculated ORs according to GRS-N quartile - the Ps OR for top vs. bottom GRS-N quartiles was 12.29 (P<1 x 10-6). The analysis of different Ps sub-phenotypes showed an association of GRS-N with age of onset and family history of Ps.
conclusionsWe confirmed the association of Ps with several previously identified genetic risk factors in a Polish population. We found that a GRS combining 16 SNPs at least nominally associated with Ps had a significantly better discriminatory ability than HLA-C or GRS combining SNPs associated with Ps after the Bonferroni correction. In contrast, adding additional SNPs to GRS did not increase significantly the discriminative power.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.